Follow

The last day for trading in the warrants of series TO 4 in Idogen AB is today, October 1, 2021

01 October 2021 - 08:45

Today, October 1, 2021, is the last day for trading in warrants of series TO 4 in Idogen AB. The subscription period for the warrants of series TO 4 runs until October 5, 2021. Each warrant of series TO 4 gives the right to subscribe for one (1) new share in Idogen. The subscription price for the TO 4 warrants is SEK 2.06 per share.

If all warrants of series TO 4 are exercised, Idogen will receive approximately MSEK 18 before issue costs. In order for the warrants not to lapse without value, the holder must actively subscribe for shares no later than October 5, 2021, or alternatively sell warrants no later than October 1, 2021. Please note that some trustees may close their registration earlier than October 5, 2021.

Summary terms and conditions of the TO 4 warrants:

  • Subscription period: September 21 – October 5, 2021
  • Issue volume: 9,121,654 warrants
  • Subscription price: SEK 2.06 SEK per share
  • Last day for trading in warrants of series TO 4: October 1, 2021
  • Press release on outcome: October 8, 2021
  • Planned date for conversion to shares: October 20, 2021

Please note that the warrants that are not exercised by October 5, 2021, or alternatively disposed of by October 1, will expire worthless. Active subscription of shares or disposal of warrants is required for the warrants not to lapse.

Exercise of subscription warrants

Nominee shareholder Subscription Warrants
If the warrant holder has Subscription Warrants in a deposit account, in an investment savings account or endowment policy (nominee shareholder ownership), subscription and payment will take place with the administrator. The warrant holder should contact their administrator well in advance for further instructions regarding exercising of the Subscription Warrants.

Directly registered Subscription Warrants (securities account)
Registration via a registration form available on the websites of Erik Penser Bank and Idogen. Payment in accordance with the instructions on the registration form. Both registration form and payment must be submitted to Erik Penser Bank by 5:00 p.m. CET on October 5, 2021 at the latest.

For more information regarding TO 4 warrants, please visit Idogen’s website

Lund, October 1, 2021
Idogen AB (publ)

For further information, please contact:
Anders Karlsson, CEO, Idogen AB
Phone: +46 (0) 709 18 00 10
Email: [email protected]

The information was submitted for publication, through the agency of the contact person set out above, for publication on October 1, 2021 at 08:45 CEST.

Certified Adviser
The company’s Certified Adviser is Erik Penser Bank AB. Contact information: Erik Penser Bank AB, Box 7405, SE-103 91 Stockholm; phone: +46 (0)8-463 80 00, email: [email protected]

Idogen (Nasdaq First North Growth Market: IDOGEN) develops tolerogenic cell therapies to prevent the patient’s immune system from attacking biological agents, transplanted organs or the body's own cells or tissue. The company’s most advanced project, IDO 8, is designed to restore the efficacy of hemophilia drugs in patients who have developed neutralizing antibodies. The company’s second project, IDO T, is being developed to prevent kidney transplant rejection. In a third program, IDO AID, Idogen is focused on the treatment of autoimmune diseases. The treatment for all indications is based on the patient's own cells and is expected to have a favorable safety profile and long-lasting effect. The potential for a short-term treatment to yield a long-term effect is a major advantage in health economics for both patients and divisions providing care

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
Idogen AB
Idogen is a Swedish biotech company engaged in developing tolerogenic cell therapies to prevent biological drugs, transplanted or body cells or tissues from being attacked by the patient's immune system. Its product IDO 8, treats patients with severe hemorrhagic disease....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More